Biopharmaceutical Aspects on the Intranasal Administration of Peptides

  • A. S. Harris
Part of the NATO ASI Series book series (NSSA, volume 125)


The intranasal route for administering peptides is probably one of the most neglected methods of delivery to the systemic circulation. Yet because of its high surface area available for absorption, its highly vasculized bed of mucosa and the fact that the nasal cavity appears to have very little metabolizing capacity all indicate that absorption across the nasal membranes is a reasonable proposition. The increasing importance which has been attached to peptides as new therapeutic agents is a consequence of the isolation and structural characterisation of various peptides, including the discovery of hypothalamic releasing hormones and pituitary hormones. The advantages of the naturally occuring peptide hormones as drug candidates have mainly been attributed to their potent pharmacological activity and their good biological tolerance. However, the disadvantages have been their broad pharmacological activity (which is often masked by a singular potent effect) and their relative short biological halflife (Table 1).


Nasal Cavity Diabetes Insipidus Nasal Spray Nasal Administration Intranasal Route 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anik, S., McRae, G., Nerenberg, C., Worden, A., Foreman, J., JiinYu, H., Kushinsky, S., Jones, R. and Vickery, B., 1984, Nasal absorption of nasarelin acetate, the decapeptide [D-Nal(2)6] LHRH, in resus monkeys. I., J. Pharm. Sci., 73: 684.PubMedCrossRefGoogle Scholar
  2. Aokif F.Y. and Crawley, J.C.W., 1976, Distribution and removal of human serum albumin — technetium 99m instilled intranasally, Br. J. Clin. Pharmacol., 3: 869.CrossRefGoogle Scholar
  3. Barltrop, D., 1963, Diabetes insipidus treated with synthetic lysine vasopressin, Lancet, i:27S.Google Scholar
  4. Bond, S.W., Hardy, J.G. and Wilson C.G., 1984, Deposition and clearance of nasal sprays, Proceedings of the Second European Congress of Biopharmaceutics and Pharmacokinetics, Salamanca, Spain, 93.Google Scholar
  5. Edwards, C.R.W., Kitau, M.J., Chard, T. and Besser G.M., 1973, Vasopressin analogue DDAVP in diabetes insipidus: Clinical and laboratory studies, Br. Med. J., 3: 375.PubMedCrossRefGoogle Scholar
  6. Evans, W.S., Borges, L.C., Kaiser, D.L., Vance, M.L., Sellers, R.P., Macleod R.M., Vale W., Rivier, J. and Thorner, M.O., 1983, Intranasal administration of human pancreatic tumor GH-release in normal men, J. Clin. Endocr. Metab., 57: 1081.PubMedCrossRefGoogle Scholar
  7. Fraser, R. and Scott, D.J., 1963, Nasal spray of synthetic vasopressin for the treatment of diabetes insipidus, Lancet, i:1159.CrossRefGoogle Scholar
  8. Greenwood, F.C., Hunter, W.M. and Glover, J.S., 1963, The preparation of 131I-labelled human growth hormone of high specific radioactivity, Biochem. J., 89: 114.PubMedGoogle Scholar
  9. Hardy, J.G., Lee, S.W.S. and Wilson, C.G., 1985, intranasal drug delivery by spray and drops, J. Pharm. Pharmacol., 37: 294.PubMedCrossRefGoogle Scholar
  10. Hoover, R.T., 1971, Intranasal oxytocin in eighteen hundred patients: A study on its safety as used in a community hospital, Am. J. Obstet. Gynec., 110: 778.Google Scholar
  11. Kobrinsky, N.L., Israels, E.D., Gerrard J.M., Cheang, M.S., Watson, C.M., Bishop, A.J. and Schroeder, M.L., 1984, Shortening of bleeding time by l-deamino-8-D-arginine vasopressin in various bleeding disorders Lancet, i:1145.CrossRefGoogle Scholar
  12. Lundin, S., Melin, P. and Vilhardt H., 1985, Plasma concentrations of l-deamino-8-D-arginine vasopressin after intragastric administration in the rat, Acta Endocrinol., 108: 179.PubMedGoogle Scholar
  13. Mannucci, P.M., Canciani, M.T., Rota, L. and Donovan, B.S., 1981, Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand’s disease, Br. J. Haematol., 47: 283.PubMedCrossRefGoogle Scholar
  14. Mannucci, P.M., Ruggeri, Z.M., Pareti, F.I. and Capitanio, A., 1977, l-deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand’s disease, Lancet, i:869.CrossRefGoogle Scholar
  15. Morimoto, K., Morisaka, K. and Kanada, A., 1985, Enhancement of nasal absorption of insulin and calciotonin using polyacrylic acid gel, J. Pharm. Pharmacol., 37: 134.PubMedCrossRefGoogle Scholar
  16. Nilsson, I.M., Vilhardt, H., Holmberg, L., Åstedt, B., 1982, Association between factor VIII related antigen and plasminogen activator, Acta Med. Scand., 211: 105.PubMedCrossRefGoogle Scholar
  17. Ohwaki, T., Ando, H., Watanabe, S. and Miyake, Y., 1985, Effects of Dose, pH, and Osmolarity on Nasal Absorption of Secretin in Rats, J. Pharm. Sci., 74: 550.PubMedCrossRefGoogle Scholar
  18. Richardson, D.W. and Robinson A.G., 1985, Desmopressin, Ann. Int. Med., 103: 228.PubMedCrossRefGoogle Scholar
  19. Rosen, S., Owaldsson, U., Blombäck, M., Larrieu, M., Nilsson I.M. and Vinazzer H., 1984, Evaluation of a chromogenic method for determining F VIII:C in hemophiliacs, von Willebrand patients and F VIII concentrate, Scand. J. Haematol., Suppl 40, 33: 93.Google Scholar
  20. Ruggeri, Z.M., Mannucci, P.M., Jeffcoate, S.L. and Ingram, G.I.C., 1976, Immunoradiometric assay of factor VIII related antigen, with observations in 32 patients with von Willebrand’s disease, Br. J. Haematol., 33: 221.PubMedCrossRefGoogle Scholar
  21. Sandow, J. and Petri W., 1985, Intranasal administration of peptides biological activity and therapeutic efficacy, in: “Transnasal Systemic Medications,” Y.W. Chien, ed., Elsevier Science Publishers B.V., Amsterdam.Google Scholar
  22. Sofroniew, M.W., Madler, M., Müller, O.H. and Scriba, P.C., 1978, A method for the consistent production of high quality antisera to small peptide hormones, Fresenius Z. Anal. Chem., 290: 163.CrossRefGoogle Scholar
  23. Vavra, I., Machova, A., Holecek, V., Cort, J.H., Zaoral, M. and Sorm, F., 1968, Effect of a synthetic analogue of vasopressin in animals and in patients with diabetes insipidus Lancet, i:948.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1986

Authors and Affiliations

  • A. S. Harris
    • 1
  1. 1.Ferring ABMalmöSweden

Personalised recommendations